Tiziana Life Sciences LTD

Quick facts

Phase 2 pipeline

• Foralumab Nasal · Autoimmune diseases
  Foralumab Nasal is an anti-CD3 monoclonal antibody that modulates the immune system.
• Foralumab TZLS-401 100 µg

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Tiziana Life Sciences LTD portfolio CI brief
• Tiziana Life Sciences LTD pipeline updates RSS